<SEC-DOCUMENT>0001062993-17-005167.txt : 20171205
<SEC-HEADER>0001062993-17-005167.hdr.sgml : 20171205
<ACCEPTANCE-DATETIME>20171205115451
ACCESSION NUMBER:		0001062993-17-005167
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171201
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171205
DATE AS OF CHANGE:		20171205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		171239039

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>December
1, 2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="59%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="41%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="41%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=justify>Emerging growth company </P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.</P>
<P align=justify><B>Item
3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unregistered Sales of
Equity Securities </B></P>
<P align=justify>Lexaria has received US$6,733.02<B> </B>from the exercise of a
compensation option certificate previously granted. The compensation option
certificate was exercised at the price of US$0.42 and a total of 16,031 common
shares are being issued. This exercise is by a third party who is neither an
officer nor a director of the Company. The Company has also issued 8,016 warrants with
an exercise price of US$0.60 and an expiration date of April 3, 2019, related to
the compensation option certificate. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify>Lexaria is issuing 14,634 restricted common shares at an
issuance price of US$0.82 per shares to settle US$12,000 of debt to a director
of the Company. </P>
<P align=justify>Lexaria is granting 200,000 stock options with an exercise
price of US$0.83 and an expiration date of December 1, 2022 to an officer of the
Company, pursuant to an existing management contract. Lexaria is awarding
250,000 stock warrants with an exercise price of US$0.83 and an expiration date
of December 1, 2019 to a manager of the Company, pursuant to a management
contract. </P>
<P align=justify>Lexaria is awarding a total of 209,056 restricted common shares
at an issuance price of US$0.82 as required by intellectual property performance
thresholds within an existing management consulting contract with the Company
divided between three officers and three managers. </P>
<P align=justify>Following issuance of these common shares, Lexaria will have
69,674,919 common shares issued and outstanding. No commissions or placement
fees have been paid related to the funds received from these warrants exercised.
Proceeds will be used for general corporate purposes.</P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.</B> </P>
<P align=justify><B>Item
7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure
</B></P>
<P align=justify>A copy of the news release announcing that Lexaria has received
US$6,733.02<B> </B>from the exercise of a compensation option certificate
previously granted is filed as exhibit 99.1 to this current report and is hereby
incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01</B> </TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits</B> </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated December 1,
      2017 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: December 1, 2017 </TD>
    <TD align=left width="50%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="50%">&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 -Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Announces Option and Warrant Transactions. </B></P>
<P align=justify>Kelowna, British Columbia &#150; December 1, 2017 &#150; Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) announces
various stock, option and warrant transactions.</P>
<P align=justify>Lexaria announces it has received US$6,733.02<B> </B>from the
exercise of a compensation option certificate previously granted. The
compensation option certificate was exercised at the price of US$0.42 and a
total of 16,031 common shares are being issued. This exercise is by a third
party who is neither an officer nor a director of the Company. The Company has
also issued 8,016 warrants with an exercise price of US$0.60 and an expiration
date of April 3, 2019, related to the compensation option certificate. </P>
<P align=justify>Lexaria is issuing 14,634 restricted common shares at an
issuance price of US$0.82 per shares to settle US$12,000 of debt to a director
of the Company. </P>
<P align=justify>Lexaria is granting 200,000 stock options with an exercise
price of US$0.83 and an expiration date of December 1, 2022 to an officer of the
Company, pursuant to an existing management contract. Lexaria is awarding
250,000 stock warrants with an exercise price of US$0.83 and an expiration date
of December 1, 2019 to a manager of the Company, pursuant to a management
contract. </P>
<P align=justify>Lexaria is awarding a total of 209,056 restricted common shares
at an issuance price of US$0.82 as required by intellectual property performance
thresholds within an existing management consulting contract with the Company
divided between three officers and three managers.</P>
<P align=justify> Following issuance of these
  common shares, Lexaria will have 69,674,919 common shares issued and
  outstanding. No commissions or placement fees have been paid related to the
  funds received from these warrants exercised. Proceeds will be used for general
  corporate purposes.</P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. </B></P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive patented technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and was granted its first patents in the USA and in Australia
related to edible forms of cannabinoids. Lexaria&#146;s technology provides increases
in intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <BR><U>www.lexariabioscience.com </U></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A><br>
<IMG
src="exhibit99-1x2x1.jpg"
border=0> <BR>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U>www.NetworkNewsWire.com
</U><BR>
</P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria&#146;s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPova<SUP>TM </SUP>products are not intended to
diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99-1x2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x2x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !# 1<# 2(  A$! Q$!_\0
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
